References of "Stevenaert, Achille"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMalignant prolactinoma discovered by D2 receptor imaging.
Petrossians, Patrick ULg; de Herder, W.; Kwekkeboom, D. et al

in Journal of Clinical Endocrinology and Metabolism (2000), 85(1), 398-401

Detailed reference viewed: 16 (0 ULg)
See detailFamilial Isolated pituitary adenomas not related to the MEN-1 syndrome : A study of 27 patients
Valdes Socin, Hernan Gonzalo ULg; Betea, Daniela ULg; Stevens, V. et al

in 10th Meeting of the Belgian Endocrine Society, 2 December 2000 (2000)

Detailed reference viewed: 14 (0 ULg)
See detailAdénomes hypophysaires familiaux isolés non liés avec la mutation somatique NEM-1 : Suivi de 27 patients
Valdes Socin, Hernan Gonzalo ULg; Poncin, J.; Stevens, V. et al

in XVIIIème Congrès de la Société Française d'Endocrinologie - Abstract book (2000)

Detailed reference viewed: 11 (0 ULg)
See detailTraitement complémentaire par radiothérapie stéréotaxique fractionnée dans les adénomes hypophysaires : suivi de 22 patients
Valdes Socin, Hernan Gonzalo ULg; Rutten, I.; Kaschten, Bruno ULg et al

in XVIIIème Congrès de la Société Française d'Endocrinologie - Abstract book (2000)

Detailed reference viewed: 18 (0 ULg)
See detailAdénomes hypophysaires producteurs de TSH : Suivi à long terme de 40 cas
Valdes Socin, Hernan Gonzalo ULg; Chanson, P.; Delemer, B. et al

in XVIIIème Congrès de la Société Française d'Endocrinologie - Abstract book (2000)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailCabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst, Johan; Abs, Roger; Maiter, Dominique et al

in Journal of Clinical Endocrinology and Metabolism (1999), 84(7), 2518-22

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number ... [more ▼]

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 microg/L (range, 16-26,250 microg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. [less ▲]

Detailed reference viewed: 58 (2 ULg)
See detailEffets antitumoraux des agonistes dopaminergiques et des analogues de la somatostatine
Beckers, Albert ULg; Valdes Socin, Hernan Gonzalo ULg; Stevenaert, Achille ULg

in Médecine Thérapeutique Endocrinologie (1999), 1(2), 183-191

Le traitement médicamenteux des adénomes hypophysaires commence son histoire au début des années 70. La bromocriptine qui vient d’être découverte s’avère efficace pour traiter l’hyperprolactinémie et ... [more ▼]

Le traitement médicamenteux des adénomes hypophysaires commence son histoire au début des années 70. La bromocriptine qui vient d’être découverte s’avère efficace pour traiter l’hyperprolactinémie et restaurer la fertilité chez les femmes hyperprolactinémiques. Son effet antitumoral est découvert un peu plus tard lorsque des scanners performants permettent d’observer une diminution de volume de l’adénome. Au cours des vingt dernières années, des progrès substantiels ont été accomplis dans le traitement médical des adénomes hypophysaires et dans les techniques qui permettent leur observation et leur suivi. Des molécules plus puissantes que la bromocriptine sont maintenant disponibles pour le traitement des adénomes à prolactine (PRL). Les plus utilisées et les plus connues sont le quinagolide et la cabergoline. En outre, de nouveaux traitements médicamenteux, s’adressant cette fois à l’adénome somatotrope, ont vu le jour. La somatostatine a été découverte en 1973. Sa demi-vie très courte et les effets rebond observés après son injection ne permettaient toutefois pas de l’utiliser pour soigner l’acromégalie. Il a fallu attendre le milieu des années 80 pour disposer du premier analogue efficace dans cette indication : l’octréotide. Depuis, les préparations à effet retard ont vu le jour (Sandostatine® LAR, Somatuline® LP). Elles permettent une normalisation de la sécrétion de l’hormone de croissance (growth hormone, GH) dans l’acromégalie dans plus de la moitié des cas. Il est rapidement devenu évident que ces médicaments étaient aussi capables d’entraîner une réduction du volume des adénomes dans un pourcentage significatif de cas. Parallèlement, les progrès techniques ont permis la mise au point de scanners hyperperformants et, surtout, d’examens par résonance magnétique nucléaire (IRM). Actuellement, ce type d’examens a remplacé le scanner dans l’évaluation des adénomes hypophysaires. Il permet, en effet, de repérer des lésions de plus petite taille qu’avant, de mieux définir les limites entre la tumeur, l’hypophyse normale et les structures avoisinantes, notamment dans les macro-adénomes, et, en outre, de mieux caractériser les phénomènes intratumoraux tels que la nécrose ou l’hémorragie. Dans cet article nous revoyons les effets antitumoraux des analogues de la somatostatine et des agonistes dopaminergiques dans l’acromégalie et chez les patients porteurs d’adénome à prolactine. Les divers types de réponses, aussi bien dans les micro-adénomes que dans les macro-adénomes, seront envisagés à l’occasion de la description de cas cliniques illustratifs, puis une synthèse générale sera présentée. [less ▲]

Detailed reference viewed: 85 (0 ULg)
Full Text
See detailL'acromégalie
Beckers, Albert ULg; Stevenaert, Achille ULg

in Tempo Médical (1999), 204

Les premières descriptions d'acromégalie ont été effectuées à la fin du siècle dernier par Pierre MARIE (1886). Cette affection, caractérisée par une hypersécrétion d'hormone de croissance a été longtemps ... [more ▼]

Les premières descriptions d'acromégalie ont été effectuées à la fin du siècle dernier par Pierre MARIE (1886). Cette affection, caractérisée par une hypersécrétion d'hormone de croissance a été longtemps considérée comme rare. En raison de sa progression insidieuse, elle est souvent diagnostiquée très tardivement. Dans cet article, nous illustrons le cas d'une patiente chez qui le diagnostic d'acromégalie a été posé au cours d'une opération pour adénocarcinome colique. [less ▲]

Detailed reference viewed: 63 (2 ULg)
Peer Reviewed
See detailUne étiologie immunologique à l'hyperprolactinemie: la macroprolactinémie
Lebrun, Yves ULg; Luyckx, Françoise ULg; Brue, T. et al

in Revue Médicale de Liège (1999), 54(9), 759-63

Besides classical etiologies of hyperprolactinaemia (pregnancy, pharmacological treatments, pituitary or hypothalamic perturbations), another less known cause may explain a spectacular idiopathic ... [more ▼]

Besides classical etiologies of hyperprolactinaemia (pregnancy, pharmacological treatments, pituitary or hypothalamic perturbations), another less known cause may explain a spectacular idiopathic elevation of plasma concentrations of prolactin hormone. Macroprolactinaemia is characterized by the presence of a circulating high molecular weight complex of prolactin with an immunoglobulin G. In this article, we report the cases of 3 female patients for whom size exclusion chromatography technique permitted to give a precise biological diagnosis and to avoid heavy, expensive, time consuming and unnecessary clinical investigations or therapeutic actions. Patients with macroprolactinaemia do not exhibit clinical features of classical hyperprolactinaemia, notably as regard to menstrual and fertility disturbances. [less ▲]

Detailed reference viewed: 127 (0 ULg)
Full Text
Peer Reviewed
See detailSomatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis.
Poncin, Jacques ULg; Stevenaert, Achille ULg; Beckers, Albert ULg

in European Journal of Endocrinology (1999), 140(6), 573-6

Pituitary adenomas are a common manifestation of multiple endocrine neoplasia type 1 (MEN1) but most of them occur sporadically. There are only a few well defined genetic abnormalities known to occur in ... [more ▼]

Pituitary adenomas are a common manifestation of multiple endocrine neoplasia type 1 (MEN1) but most of them occur sporadically. There are only a few well defined genetic abnormalities known to occur in these sporadic tumours. The MEN1 gene located on 11q13 has recently been cloned and allelic deletion and mutation analysis studies have implicated the MEN1 gene in a significant fraction of the sporadic counterparts of typical MEN1 neoplasms (parathyroid tumours, insulinomas and gastrinomas). To determine if MEN1 gene inactivation is also involved in the development of sporadic pituitary adenomas, allelic deletions of chromosome 11q13 and MEN1 gene mutations and polymorphisms were assessed in 35 sporadic tumours of the anterior pituitary (9 prolactin-secreting, 8 GH-secreting, 3 TSH-secreting, 2 TSH/GH-secreting, 4 Cushing, 9 silent). Thirty-one tumours were found to be heterozygous for at least one MEN1 intragenic polymorphism (25 cases) or for a flanking gene polymorphism (6 cases). The remaining tumours were not informative. No mutations were found in any tumour except in one prolactinoma which was homozygous or hemizygous for a mutation (1-117 C-->T) in a region close to the promoter. Unfortunately, blood or normal tissue was not available in this case. Our data show that somatic MEN1 mutations do not contribute significantly to tumorigenesis of sporadic pituitary adenomas and suggest that mutation of other genes are likely to contribute to the pathogenesis of these tumours. [less ▲]

Detailed reference viewed: 32 (0 ULg)
Full Text
Peer Reviewed
See detailFamilial Acromegaly: Case Report and Review of the Literature
Verloes, Alain ULg; Stevenaert, Achille ULg; Teh, B. T. et al

in Pituitary (1999), 1(3-4), 273-277

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been ... [more ▼]

Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of action of the gene responsible of familial acromegaly, but no data have been published to sustain or reject this hypothesis. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Peer Reviewed
See detailLes encéphalocèles antérieurs: à propos de deux cas.
Collignon, F.; Martin, Didier ULg; Stevenaert, Achille ULg

Conference (1999, March 13)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPosterior epidural migration of sequestered lumbar disc fragments. Report of two cases.
Robe, Pierre ULg; Martin, Didier ULg; Lenelle, Jacques ULg et al

in Journal of Neurosurgery (1999), 90(2 Suppl), 264-6

The posterior epidural migration of sequestered lumbar disc fragments is an uncommon event. The authors report two such cases in which patients presented with either intense radicular pain or cauda equina ... [more ▼]

The posterior epidural migration of sequestered lumbar disc fragments is an uncommon event. The authors report two such cases in which patients presented with either intense radicular pain or cauda equina syndrome. The radiological characteristics were the posterior epidural location and the ring enhancement of the mass after injection of contrast material. The major diagnostic pitfalls are discussed. [less ▲]

Detailed reference viewed: 98 (7 ULg)
See detailCabergoline in the treatment of Hyoerprolactinemia : A study in 455 patients
Verhelst, J.; Abs, R.; Maiter, D. et al

in 9th Meeting and workshop of the European Neuroendocrine Association - Abstract book (1999)

Detailed reference viewed: 3 (0 ULg)
See detailFamilial Acromegaly : Case report and review of the litterature
Beckers, Albert ULg; Stevenaert, Achille ULg; Teh, B. T. et al

in The 6th International Pituitary Congress - Abstract book (1999)

Detailed reference viewed: 4 (0 ULg)
See detailHypophyseal failure and amaurosis revealing an extensive inflammatory pseudotumor
Hansen, I.; Ronci, N.; Stevenaert, Achille ULg et al

in The 6th International Pituitary Congress - Abstract book (1999)

Detailed reference viewed: 3 (0 ULg)
See detailShrinkage of a ACTH silen adenomas under cabergoline treatment : report
Khalife, A.; Ronci, N.; Stevenaert, Achille ULg et al

in The 6th International Pituitary Congress - Abstract book (1999)

Detailed reference viewed: 3 (0 ULg)
See detailDiminution de volume d'un macro-adénome à ACTH (silencieux) sous Cabergoline
Khalife, A.; Ronci, N.; Stevenaert, Achille ULg et al

in XVIIème Congrès de la Société Française d'Endocrinologie - Abstract book (1999)

Detailed reference viewed: 5 (0 ULg)
See detailExpression of somatostatin receptor subtypes 2 and 5 in human prolactinomas
Baillet, L.; Ronci, N.; Epelbaum, J. et al

in 81st Annual Meeting of the Endocrine society - Abstract book (1999)

Detailed reference viewed: 4 (0 ULg)